Google this exact article name (use quotes):
"Will Physicians REGARD Ramucirumab as a Viable Option in Relapsed Gastric Cancer?"
DYAX pps gapped up on Oct.13, 2012 when favorable top-line results were released for Ramucirumab. Later, full data was released at ASCO, and the story was not so cut-and-dried. Players have been lightening up on DYAX since then, and DYAX pps has been looking for a bottom.
Ramucirumab's chances for approval seem to have diminished compared to how good they looked on Oct. 13, but they are not zero. If Ramucirumab is approved, DYAX will collect royalties on it from Lilly. If not, DYAX's steady quarter-over-quarter growth will continue unaffected by it one way or the other.
On LLY's CC right now. The are going ahead with plans to seek approval for Ramicirumab. Already talking with regulators. They were very positive on the drug being the only potential second line treatment for gastric cancers.